Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

NCT06727565 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Domvanalimab
DRUG: Zimberelimab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Gilead Sciences

Collaborators

[object Object]